000			01837 a2200493 4500
005			20250513221431.0
264		0	_c20001010
008			200010s 0 0 eng d
022			_a0098-7484
024	7		_a10.1001/jama.284.12.1549 _2doi
040			_aNLM _beng _cNLM
100	1		_aBhatt, D L
245	0	0	_aCurrent role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. _h[electronic resource]
260			_bJAMA _cSep 2000
300			_a1549-58 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAbciximab
650	0	4	_aAcute Disease
650	0	4	_aAlanine _xtherapeutic use
650	0	4	_aAngina, Unstable _xdrug therapy
650	0	4	_aAngioplasty, Balloon, Coronary
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAnticoagulants _xtherapeutic use
650	0	4	_aBenzamidines _xtherapeutic use
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEptifibatide
650	0	4	_aHeparin, Low-Molecular-Weight _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Fab Fragments _xadministration & dosage
650	0	4	_aMyocardial Infarction _xdrug therapy
650	0	4	_aOximes _xtherapeutic use
650	0	4	_aPeptides _xadministration & dosage
650	0	4	_aPiperidines _xtherapeutic use
650	0	4	_aPlatelet Aggregation Inhibitors _xadministration & dosage
650	0	4	_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors
650	0	4	_aPyrrolidines _xtherapeutic use
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aStents
650	0	4	_aTirofiban
650	0	4	_aTyrosine _xadministration & dosage
700	1		_aTopol, E J
773	0		_tJAMA _gvol. 284 _gno. 12 _gp. 1549-58
856	4	0	_uhttps://doi.org/10.1001/jama.284.12.1549 _zAvailable from publisher's website
999			_c10946836 _d10946836